Home / Clinical areas / Oncology

Oncology

Sequencing Panels

Oncohematology

Myeloproliferative neoplasms
  • Polycythemia vera – JAK2 (exon 12) [1 gene]

    Ref.: S-202008868|Turnaround time (TAT) 25 days

  • JAK2. Detection of the V617F mutation [1 gene]

    Ref.: S-202212572|Turnaround time 25 days

  • Detection of the mutations c.1544G>T (p.Trp515Leu) and c.1514G>A (p.Ser505Asn) in MPL gene [1 gene]

    Ref.: S-202212470|Turnaround time (TAT) 20 days

  • Exon 9 in CALR gene [1 gene]

    Ref.: S-202212296|Turnaround time (TAT) 20 days

  • Detection of BCR/ABL1 rearrangement [2 genes]

    Ref.: S-202212976|Turnaround time (TAT) 6 days

  • Quantification of BCR/ABL1 rearrangement [2 genes]

    Ref.: S-202212446|Turnaround time (TAT) 6 days

  • Detection of the p.T618I mutation in CSF3R gene [1 gene]

    Ref.: S-202009668|Turnaround time (TAT) 20 days

  • Detection of the D816V mutation in c-KIT gene [1 gene]

    Ref.: S-202009330|Turnaround time (TAT) 20 days

Myeloid and lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB, or FGFR1 anomalies
  • Detection of FIP1L1/PDGFRA rearrangement [2 genes]

    Ref.: S-202110214|Turnaround time (TAT) 6 days

Myelodysplastic syndromes
  • Myelodysplastic syndrome: K700E mutation in SF3B1 gene [1 gene]

    Ref.: S-202009328|Turnaround time (TAT) 20 days

  • Myelodysplastic syndrome: sequencing of TP53 gene [1 gene]

    Ref.: S-202009329|Turnaround time (TAT) 25 days

  • Myelodysplastic syndrome: MLPA of TP53 gene [1 gene]

    Ref.: S-202009669|Turnaround time (TAT) 20 days

Acute myeloid leukemias
  • Detection of PML/RARa rearrangement [2 genes]

    Ref.: S-202212447|Turnaround time (TAT) 20 days

  • Quantification of PML/RARa rearrangement [2 genes]

    Ref.: S-202212844|Turnaround time (TAT) 20 days

  • Detection of AML1/ETO rearrangement [2 genes]

    Ref.: S-202313411|Turnaround time (TAT) 20 days

  • Quantification of AML1/ETO rearrangement [2 genes]

    Ref.: S-202313407|Turnaround time (TAT) 20 days

  • Mutations in NPM1 gene (exon 12) [1 gene]

    Ref.: S-202009326|Turnaround time (TAT) 20 days

Lymphoblastic leukemias
  • B-cell clonality [B-cell clonality]

    Ref.: S-202212919|Turnaround time (TAT) 6 days

  • T-cell clonality [T-cell clonality]

    Ref.: S-202212920|Turnaround time (TAT) 6 days

Acute lymphoblastic leukemia
  • Detection of TEL/AML1 rearrangement [2 genes]

    Ref.: S-202313408|Turnaround time (TAT) 20 days

  • Detection of MLL/AF4 rearrangement [2 genes]

    Ref.: S-202212457|Turnaround time (TAT) 20 days

Lymphomas
  • IgH/BCL2 t(14;18) rearrangement [2 genes]

    Ref.: S-202313409|Turnaround time (TAT) 25 days

  • CCND1/IgH t(11;14) rearrangement [2 genes]

    Ref.: S-202313410|Turnaround time (TAT) 25 days

Waldenström macroglobulinemia
  • Macroglobulinemia: p.L265P mutation in MYD88 gene [1 gene]

    Ref.: S-202009332|Turnaround time (TAT) 25 days

  • Macroglobulinemia: CXCR4 gene sequencing [1 gene]

    Ref.: S-202009331|Turnaround time (TAT) 25 days

  • Screening of informative marker for chimerism [RT-PCR]

    Ref.: S-202212380|Turnaround time (TAT) 5 days

  • Monitoring of chimerisms via dPCR [RT-PCR]

    Ref.: S-202212381|Turnaround time (TAT) 5 days

Inés Calabria, PhD

Head of the area of Oncology

Informed consent form Steps to follow Need counseling?
Steps to follow
Click here to see the Guidelines for the collection and transport of biological samples

1) Download & fill out

Please cover as many fields as possible in both documents

2) Sample collection

See sample types in the guidelines

3) Pack the sample

Please pack the sample in a way to prevent leakage

4) Send the sample & the request

Please schedule the delivery for Monday–Friday: 8am – 5pm

5) Result: the report

Via: e-mail and/or through the customer portal

Ask us for more information on our oncology services

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Consentimiento*
Global panel of oncohematological diseases – 76 genes

ARID5B, ASXL1, ASXL2, ATRX, BCOR, BCORL1, BLNK, BRAF, CALR, CBL, CDKN2A, CDKN2B, CEBPA, CHIC2, CREBBP, CSF3R, CSNK1A1, CUX1, DDX3X, DDX41, DNMT3A, EP300, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2 (+I4), GATA3, HAVCR2, IDH1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KIT, KMT2A, KMT2C, KRAS, MPL, NF1, NFE2, NOTCH1, NPM1, NR3C1, NRAS, P2RY8, PAX5, PHF6, PIGA, PPM1D, PTEN, PTK2B, PTPN11, RAD21, RB1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRP72, SRSF2, STAG1, STAG2, STAT5B, TET2, TP53, TYK2, U2AF1, WT1, ZRSR2

Polycythemia vera – JAK2 (exon 12) – 1 gene

JAK2

JAK2. Detection of the V617F mutation – 1 gene

JAK2

Detection of the mutations c.1544G>T (p.Trp515Leu) and c.1514G>A (p.Ser505Asn) in MPL gene – 1 gene

MPL

Exon 9 in CALR gene – 1 gene

CALR

Detection of BCR/ABL1 rearrangement – 2 genes

ABL1/BCR

Quantification of BCR/ABL1 rearrangement – 2 genes

ABL1/BCR

Detection of the p.T618I mutation in CSF3R gene – 1 gene

CSF3R

Detection of the D816V mutation in c-KIT gene – 1 gene

c-KIT

Detection of FIP1L1/PDGFRA rearrangement – 2 genes

FIP1L1/PDGFRA

Myelodysplastic syndrome: K700E mutation in SF3B1 gene – 1 gene

SF3B1

Myelodysplastic syndrome: sequencing of TP53 gene – 1 gene

TP53

Myelodysplastic syndrome: MLPA of TP53 gene – 1 gene

TP53

Detection of PML/RARa rearrangement – 2 genes

PML/RARa

Quantification of PML/RARa rearrangement – 2 genes

PML/RARa

Detection of AML1/ETO rearrangement – 2 genes

AML1/ETO

Quantification of AML1/ETO rearrangement – 2 genes

AML1/ETO

Mutations in NPM1 gene (exon 12) – 1 gene

NPM1

Detection of TEL/AML1 rearrangement – 2 genes

TEL/AML1

Detection of MLL/AF4 rearrangement – 2 genes

TEL/AML1

IgH/BCL2 t(14;18) rearrangement – 2 genes

IgH/BCL2 t(14;18)

CCND1/IgH t(11;14) rearrangement – 2 genes

CCND1/IgH t(11;14)

Macroglobulinemia: p.L265P mutation in MYD88 gene – 1 gene

MYD88

Macroglobulinemia: CXCR4 gene sequencing – 1 gene

CXCR4